← All trials
NCT03606213
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2018
- Primary completion
- Dec 1, 2020
- Completion date
- Dec 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 60
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of California, San FranciscoLead sponsor
- Inovio PharmaceuticalsCollaborator
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- University of California, San FranciscoOverall official - principal investigator
- University of California, San FranciscoSponsor investigator
- University of California, San FranciscoOfficial
- University of California, Los AngelesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.